Reactive oxygen species

The Root Brands Releases its 7th product Mitochondria Defense Shield with NAD

Retrieved on: 
Saturday, August 6, 2022 - 1:24am

Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.

Key Points: 
  • Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.
  • Mitochondria are tiny double membrane-bound organelles found in almost every cell of all organisms except bacteria, they are known as "the powerhouse of the cell".
  • It enters the mitochondria in its oxidized form and protects mitochondria from oxidative injury.
  • Vitamin D is vital for regulating the absorption of calcium and phosphorus and facilitating normal immune system function.

OXEIA ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 2 TRIAL FOR OXE103 FOR THE TREATMENT OF CONCUSSIONS

Retrieved on: 
Wednesday, August 3, 2022 - 5:49pm

The trial is focusing on treatment for subjects within 28 days of injury who are highly symptomatic at screening.

Key Points: 
  • The trial is focusing on treatment for subjects within 28 days of injury who are highly symptomatic at screening.
  • This group represents the majority of concussion patients who do not seek treatment immediately following their injury.
  • According to Oxeia CEO, Dr. Michael Wyand, I am encouraged by the interim results we are seeing from the trial.
  • The interim data provide hope for an effective treatment for the millions of people who suffer ongoing post-concussion symptoms due to a lack of effective treatment options.

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Retrieved on: 
Friday, July 29, 2022 - 12:30pm

SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Companys ongoing U.S.

Key Points: 
  • SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Companys ongoing U.S.
  • Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.
  • If positive trends are observed in favor of the Tempol treatment group, the DSMB may recommend continuing the study along with the enrollment of additional subjects.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.

Award-winning Taiwan Tech Start-up ELECLEAN CO., LTD launches new AI water treatment system at the World's Biggest Tech Show

Retrieved on: 
Friday, July 29, 2022 - 4:58am

TAIPEI, July 28, 2022 /PRNewswire/ -- Taiwanese company ELECLEAN CO. is launching its versatile "electro-oxidation" water treatment system known as ELECLEAN Water at CES 2022.

Key Points: 
  • TAIPEI, July 28, 2022 /PRNewswire/ -- Taiwanese company ELECLEAN CO. is launching its versatile "electro-oxidation" water treatment system known as ELECLEAN Water at CES 2022.
  • It can purify water at home, and even meet the stringent demands of the medical and semiconductor industries.
  • Because water is the single reagent required by ELECLEAN Water, no harmful preservatives are generated from the water purification process.
  • Compared with conventional water purification systems, ELECLEAN Water boasts an increased purified water production capacity and is sleek in appearance.

MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

Retrieved on: 
Thursday, July 7, 2022 - 12:00pm

YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced positive results from its U.S. prospective, open-label, single-arm, Phase 2 pharmacology clinical study of EscharEx® for the debridement of lower leg ulcers.

Key Points: 
  • The study was designed to evaluate the clinical performance, safety and pharmacology effect of EscharEx in debridement of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).
  • The U.S. phase 2 pharmacology study was a prospective, open label, single-arm study, being conducted at three U.S. clinical sites.
  • The study evaluated the clinical performance, safety, and pharmacology effect of EscharEx in the debridement of lower leg ulcers (VLUs and DFUs).
  • The study evaluated the safety and efficacy of debridement as measured by incidence of, and time to complete debridement.

Brand Institute Partners on Brand Name Development for Treatment of Relapsed or Refractor Peripheral T-Cell Lymphoma Now Approved by Ministry of Health, Labour and Welfare (Japan)

Retrieved on: 
Tuesday, July 5, 2022 - 2:00pm

DARVIAS, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.

Key Points: 
  • DARVIAS, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.
  • DARVIAS has been approved for relapsed or refractory Peripheral T-Cell Lymphoma by Japan's Ministry of Health, Labour and Welfare (MHLW).
  • "The entire Brand Institute and Drug Safety Institute team congratulates Solasia on the MHLW approval of the DARVIAS injection," said Brand Institute's Chairman and C.E.O., James L. Dettore.
  • The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers.

TREE: SelectUSA-awarded Taiwan startups met Bay Area founders and investors

Retrieved on: 
Tuesday, July 5, 2022 - 4:23am

"Taiwan government is very supportive of tech innovation, especially those deep tech startups from research institutions," said Dr. Chyou-Huey Chiou, Director General of the DoIT.

Key Points: 
  • "Taiwan government is very supportive of tech innovation, especially those deep tech startups from research institutions," said Dr. Chyou-Huey Chiou, Director General of the DoIT.
  • After the summit, those startups were invited by the U.S. government (American Institute in Taiwan and San Francisco City) to visit the Bay Area to exchange ideas with local innovative startups.
  • U.S. startup founders were impressed by technical capabilities of Taiwan startups: Atayalan Technology offers enterprises with optimized 5G private network management software technology.
  • Those six startups also visited Bay Area investors, including Tim Draper and Chih-Kai Cheng, Chair of B Current Impact Investment.

Fisetin: A Little-known Nutrient that Could Lead to Breakthroughs in Longevity & Cognitive Health, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, June 28, 2022 - 1:25pm

TORONTO, June 28, 2022 /PRNewswire-PRWeb/ -- Advancement in nutrition and medical sciences have increased life expectancy in most developed countries. However, increased life expectancy brings associated aging problems in a significant proportion of the population. These include neurodegenerative diseases, Alzheimer's disease, diabetes, osteoarthritis, atherosclerosis and vision problems. Recent research has identified the accumulation of senescent cells as a contributor to age-related issues. Here, the featured speakers discuss the potential benefits of a little-known nutrient called fisetin for tackling these issues.

Key Points: 
  • TORONTO, June 28, 2022 /PRNewswire-PRWeb/ -- Advancement in nutrition and medical sciences have increased life expectancy in most developed countries.
  • Here, the featured speakers discuss the potential benefits of a little-known nutrient called fisetin for tackling these issues.
  • Join this webinar to examine current consumer health trends related to healthy aging and cognitive health.
  • For more information, or to register for this event, visit Fisetin: A Little-known Nutrient that Could Lead to Breakthroughs in Longevity & Cognitive Health.

Theralase Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, June 28, 2022 - 12:00pm

Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).

Key Points: 
  • Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).
  • The patent advances Theralases intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (ACT) platform.
  • This patent further strengthens the extensive portfolio of patents already held by Theralase.
  • Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer (CEO) and Chief Scientific Officer (CSO), Theralase stated that, This patent is strategic to opening up new international opportunities for Theralase by expanding its IP portfolio of medical laser and oncology focused technologies internationally.

Bold Therapeutics' BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conference

Retrieved on: 
Friday, June 24, 2022 - 12:58pm

VANCOUVER, BC, June 24, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they will be attending the Metals in Medicine Gordon Research Conference focusing on Advancing the Use of Metal-Based Compounds and Nanotheranostics for Personalized Medicine.

Key Points: 
  • VANCOUVER, BC, June 24, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they will be attending the Metals in Medicine Gordon Research Conference focusing on Advancing the Use of Metal-Based Compounds and Nanotheranostics for Personalized Medicine.
  • Adam Carie, Director of CMC & Nonclinical Development, will be presenting on behalf of Bold Therapeutics in the "Clinical Advances for Metals in Medicine" session.
  • "Bold Therapeutics is excited to present these remarkable results at the Gordon Research Metals in Medicine Conference showcasing the cutting-edge, multi-disciplinary work being performed at Vancouver-based Bold Therapeutics" noted Dr. Carie.
  • For more information about Bold Therapeutics, please visit: https://www.bold-therapeutics.com/
    For more information about the Gordon Research Conference, please visit: